St. Louis Financial Planners Asset Management, LLC just went out and bought 14,630 shares of AbbVie (ABBV), tossing roughly $3.39 million onto the table in Q3 2025. They did it with the quiet confidence of someone who knows the universe doesn’t care, but money does. So it goes.
What happened
The Securities and Exchange Commission, the bureaucratic Big Brother who keeps count, noted on October 2, 2025, that St. Louis Financial had opened a new position in AbbVie(ABBV). The firm’s quarter-end stake now sits at $3.39 million. It’s 2.1842% of the fund’s $155,093,822 in U.S. equities spread across 37 positions. Nothing says human ambition like tiny percentages in a sea of numbers. So it goes.
What else to know
This little venture accounts for 2.2% of the fund’s 13F assets as of September 30, 2025. Not exactly a revolution, but it moves the chess pieces.
Top holdings after the filing:
- NYSEMKT:BIL: $36.73 million (23.7% of AUM)
- NYSEMKT:TFLO: $17.27 million (11.1% of AUM)
- NASDAQ:BSCP: $10.45 million (6.7% of AUM)
- NASDAQ:PLTR: $9.23 million (6.0% of AUM)
- NASDAQ:AVGO: $5.16 million (3.3% of AUM)
As of October 1, 2025, AbbVie shares were priced at $244.38, up 24.08% over the past year. That’s beating the S&P 500 by 11.71 points. Somewhere, a stock analyst nodded sagely and then went to make coffee. So it goes.
Company Overview
| Metric | Value |
|---|---|
| Revenue (TTM) | $58.33 billion |
| Net Income (TTM) | $3.77 billion |
| Dividend Yield | 2.72% |
| Price (as of market close 2025-10-01) | $244.38 |
Company Snapshot
AbbVie’s main gig is making branded drugs that people apparently need, like HUMIRA, SKYRIZI, RINVOQ, IMBRUVICA, and BOTOX Therapeutic. They research, develop, and sell pharmaceuticals globally. Hospitals, doctors, governments-they all come knocking. Their focus? Autoimmune diseases, cancer, and the odd wrinkle. Humans, eternally fragile. So it goes.
They rely on a few big hits, but new drugs are always bubbling somewhere in their labs. The business is a mix of science, risk, and hope-a recipe that has kept the money flowing despite the occasional patent loss. So it goes.
Foolish take
AbbVie remains one of the stronger players in a market full of casualties. The Humira patent went poof, yet dividends stay stubbornly high. The Botox acquisition saddled them with debt, but the cash flows laugh in the face of numbers. Still, dependence on a handful of drugs is a cruel mistress; regulation or pricing shocks could hit like a cold slap. Interest rates, those silent saboteurs, are lurking. So it goes.
Yet Wall Street analysts shrug and call it a Buy. Five Strong Buys, thirteen Buys, nine Holds. AbbVie continues to outpace estimated EPS. Investors might die someday, but money doesn’t care. So it goes.
Glossary
Stake: The ownership or claim a firm has in a company.
Reportable AUM: Assets that must be disclosed to the SEC.
13F assets: U.S. equities reported quarterly by institutional managers.
Top holdings: Largest bets in a fund’s portfolio.
Dividend yield: Annual payouts relative to share price.
Outperforming: Beating the benchmark.
TTM: Trailing twelve months.
Branded pharmaceuticals: Trademarked prescription drugs.
Autoimmune diseases: When the body attacks itself.
Oncology: Cancer medicine.
In the end, investing is a dance with fate, spreadsheets, and human stubbornness. So it goes. 💊
Read More
- Gold Rate Forecast
- Shadows & Dividends: Five Contrarian Gems
- Tariff Folly: A Stock Market Tragedy?
- The Big Twist in PEACEMAKER Could Introduce Deep Cut DC Team
- Assessing the Peculiar Investment Terrain of Palantir Technologies
- Smart Stocks to Invest $1,000 in Right Now
- 📢 Guild Raid “Overkill Score” System Error and Temporary Adjustment to Season Ranking Calculation Notice
- Costco’s Results Inspire Reflection on Value Versus Expectations
- SWIFT’s Blockchain Gambit: 30+ Banks Chase 24/7 Cash Flow Dreams 🤑🚀
- Alibaba’s Labyrinthine Pursuit of Quick Commerce
2025-10-03 22:48